1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Alendronate |
| brand | String | Fosamax, Binosto |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Bisphosphonates|Bisphosphonate (nitrogen-containing)]] • [[:Category:Antiresorptives|Antiresorptive]] • [[:Category:Osteoporosis_medications|Osteoporosis medication]] |
| mechanism | String | '"`UNIQ--vote-000006BE-QINU`"' Drug-holiday concept (3-5 years on, 1-2 years off) emerged from FLEX and long-term safety data balancing fracture protection against atypical femoral fracture and osteonecrosis of the jaw signals'"`UNIQ--ref-000006BF-QINU`"'. |
| uses | String | '"`UNIQ--vote-000006C0-QINU`"', '"`UNIQ--vote-000006C1-QINU`"', '"`UNIQ--vote-000006C2-QINU`"' |
| starting_dose | String | Treatment 70 mg PO once weekly (or 10 mg daily); prevention 35 mg weekly (or 5 mg daily); always taken first thing in the morning with a full glass of water, remaining upright for 30 minutes |
| preparations | String | 5, 10, 35, 40, 70 mg tablets; 70 mg/75 mL oral solution; 70 mg effervescent (Binosto) |
| fda_max | String | 70 mg/week treatment; 40 mg/d for 6 months in Paget's |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Bone marker reduction within weeks; BMD improvement at 1-3 years; fracture-risk reduction documented at 3-5 years |
| duration | String | Weeks; bone retention years |
| halflife | String | Plasma ~3 hours; bone half-life ~10 years'"`UNIQ--ref-000006C3-QINU`"' |
| bioavailability | String | <1% (oral; further reduced by food, calcium, iron, antacids; hence the strict fasting/upright dosing rules)'"`UNIQ--ref-000006C4-QINU`"' |
| pregnancy | String | Long-term skeletal retention is a concern given the unknown effect on developing fetal bone; generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
